--- name: managing-ectopic-pregnancy language: en description: Guides ectopic pregnancy evaluation with beta-hCG trending and management algorithms. Use when evaluating ectopic pregnancy, trending beta-hCG, or managing ectopic treatment decisions. tags: - management - obstetrics-and-gynecology - treatment - valuation metadata: author: casemark practice_areas: - Obstetrics - Gynecology - Maternal-Fetal Medicine document_types: - Management Report skill_modes: - Management - Coordination --- # Managing Ectopic Pregnancy Guides ectopic pregnancy evaluation with serial β-hCG trending, discriminatory zone application, and evidence-based management algorithms per ACOG Practice Bulletin No. 193. ## Why This Skill Exists Ectopic pregnancy occurs in approximately 1–2% of all pregnancies and remains a leading cause of first-trimester maternal mortality. Ruptured ectopic pregnancy is a surgical emergency with potential for catastrophic hemorrhage. The critical clinical challenge is distinguishing ectopic from early intrauterine pregnancy (IUP) or pregnancy of unknown location (PUL) using serial β-hCG values and transvaginal ultrasound. The discriminatory zone — the β-hCG level above which an IUP should be visible on TVUS — is central to the diagnostic algorithm. ACOG Practice Bulletin No. 193 (Tubal Ectopic Pregnancy) establishes the diagnostic criteria, methotrexate eligibility, and surgical indications. Errors in β-hCG interpretation, premature surgical intervention on a desired IUP, or delayed diagnosis of a ruptured ectopic have devastating clinical and medicolegal consequences. --- ## Checkpoint A: Pre-Draft Intake (Mandatory) 1. **Symptoms** — abdominal/pelvic pain (unilateral vs. bilateral), vaginal bleeding, shoulder pain, dizziness, syncope? (Default: from chief complaint) 2. **LMP and estimated gestational age** — how many weeks from LMP? (Default: from history) 3. **Initial β-hCG level** — quantitative serum value and date/time drawn? (Default: from lab results) 4. **Ultrasound findings** — IUP confirmed, adnexal mass, free fluid, empty uterus? (Default: from TVUS report) 5. **Hemodynamic stability** — vital signs, orthostatic symptoms, tachycardia, hypotension? (Default: current vitals) 6. **Risk factors** — prior ectopic, prior tubal surgery, PID history, IUD in situ, IVF pregnancy, smoking? (Default: from history) 7. **Desire for future fertility** — critical for management decision (medical vs. surgical)? (Default: patient preference) 8. **Blood type and Rh status** — RhoGAM needed if Rh-negative? (Default: from prenatal or current labs) ### Documents to Request - Serial β-hCG values with dates and times - Transvaginal ultrasound reports (current and prior) - CBC, type and screen, coagulation studies - CMP (renal and liver function — required for methotrexate eligibility) - Prior operative reports (tubal surgery, prior ectopic management) - Pathology reports (if prior ectopic was treated surgically) --- ## Step 1: Apply the Diagnostic Algorithm ### β-hCG and the Discriminatory Zone The discriminatory zone is the β-hCG level above which a viable IUP should be visible on TVUS: - **Discriminatory level: 3,500 IU/L** (institutional range: 1,500–3,500 IU/L) - Above discriminatory zone + no IUP on TVUS = abnormal pregnancy (ectopic or failed IUP) - Below discriminatory zone + no IUP = **pregnancy of unknown location (PUL)** → serial β-hCG trending required ### Expected β-hCG Rise in Normal IUP - Early viable IUP: β-hCG rises by at least **53% in 48 hours** (minimum normal rise, per ACOG) - The traditional "doubling time of 48 hours" applies to early pregnancies (β-hCG < 10,000) - Slower rise may still be normal; < 53% rise in 48 hours is abnormal and suggests ectopic or nonviable IUP ### β-hCG Decline Patterns - After completed miscarriage: β-hCG should decline by ≥ 21–35% in 48 hours - Slower than expected decline suggests retained products or ectopic - Plateau (neither rising nor falling adequately) is concerning for ectopic ### Decision Matrix | Scenario | β-hCG Trend | Ultrasound | Action | |---|---|---|---| | Normal IUP | Rising ≥ 53%/48 hrs | IUP confirmed | Routine prenatal care | | Ectopic confirmed | Any level | Adnexal mass + no IUP; or extrauterine gestational sac with yolk sac/embryo | Manage ectopic (medical or surgical) | | PUL — likely viable IUP | Rising ≥ 53%/48 hrs | Empty uterus, below discriminatory zone | Repeat β-hCG in 48–72 hrs + TVUS when above discriminatory zone | | PUL — likely nonviable | Rising < 53%/48 hrs or plateauing | Empty uterus | Ectopic vs. failing IUP; consider D&C with path or serial monitoring | | PUL — declining | Falling > 50% in 48 hrs | Empty uterus | Likely completed miscarriage; follow to β-hCG < 5 | | Ruptured ectopic | Any level | Free fluid, hemodynamic instability | **Emergent surgery — do not delay** | --- ## Step 2: Methotrexate (Medical Management) ### Eligibility Criteria for Methotrexate | Criteria | Requirement | |---|---| | Hemodynamic stability | Required — unstable patients → surgery | | Ectopic mass size | ≤ 3.5 cm (per ACOG; some extend to 4 cm) | | No fetal cardiac activity on US | Required (cardiac activity = relative contraindication, higher failure rate) | | β-hCG level | < 5,000 IU/L ideal; success rate drops above 5,000 | | Patient ability to follow up | Must be able to return for serial β-hCG monitoring | | Renal function | Normal creatinine | | Hepatic function | Normal transaminases | | WBC count | > 1,500/μL | | Platelet count | > 100,000/μL | | No immunodeficiency | — | | No breastfeeding | Methotrexate is contraindicated in breastfeeding | ### Methotrexate Protocols | Protocol | Dosing | Monitoring | |---|---|---| | **Single-dose** | MTX 50 mg/m² IM (day 1) | β-hCG days 4 and 7; if < 15% decline between days 4–7, give second dose | | **Two-dose** | MTX 50 mg/m² IM days 1 and 4 | β-hCG days 4 and 7; if < 15% decline between days 4–7, give doses on days 7 and 11 | | **Multi-dose** | MTX 1 mg/kg IM on days 1, 3, 5, 7 alternating with leucovorin 0.1 mg/kg on days 2, 4, 6, 8 | β-hCG before each MTX dose; stop when 15% decline achieved | Post-methotrexate monitoring: - Weekly β-hCG until < 5 IU/L - Avoid NSAIDs, folate supplements, alcohol, and intercourse until resolved - Warn about transient β-hCG rise between days 1–4 (expected, not treatment failure) - Watch for treatment failure signs: increasing pain, hemodynamic change, rising β-hCG after day 7 --- ## Step 3: Surgical Management ### Indications for Surgery - Hemodynamic instability (ruptured ectopic) - Contraindication to methotrexate - Failed methotrexate (rising β-hCG after day 7 of second dose) - Patient preference - Fetal cardiac activity on ultrasound - β-hCG > 5,000 IU/L (higher failure rate with medical management) ### Surgical Options | Procedure | Description | Fertility Considerations | |---|---|---| | **Salpingostomy** | Linear incision over ectopic, removal of products, tube preserved | Preferred if contralateral tube is damaged or absent | | **Salpingectomy** | Complete removal of affected tube | Preferred if contralateral tube is healthy; lower recurrence risk | Post-surgical: - Follow β-hCG weekly to < 5 IU/L (persistent ectopic tissue requires retreatment in 5–20% of salpingostomy cases) - RhoGAM if Rh-negative (50 mcg if < 12 weeks, 300 mcg if ≥ 12 weeks) - Pathology confirmation of ectopic tissue --- ## Step 4: Special Situations ### Heterotopic Pregnancy - Coexisting IUP + ectopic; incidence is 1:30,000 naturally but up to 1:100 with ART - Methotrexate is **contraindicated** (would harm the IUP) - Treatment: surgical removal of ectopic with preservation of IUP ### Interstitial (Cornual) Ectopic - Located in intramural portion of the tube - Higher rupture risk with more severe hemorrhage - May present later (up to 12–16 weeks) due to myometrial distensibility - Surgical: cornual resection or cornuostomy; consider uterine artery embolization ### Cesarean Scar Ectopic - Implantation within the cesarean scar niche - Increasing incidence with rising cesarean rates - Management: methotrexate, uterine artery embolization, hysteroscopic resection, or laparotomy --- ## Checkpoint B: Post-Draft Alignment (Mandatory) 1. **Is the β-hCG trend documented** with at least two values, dates, and calculated % change? 2. **Is the discriminatory zone applied correctly** — and does the action match the scenario? 3. **Are methotrexate eligibility criteria checked** before recommending medical management? 4. **Is Rh status addressed** with RhoGAM administered or planned if Rh-negative? 5. **Is the follow-up plan explicit** — serial β-hCG schedule, return precautions, and failure criteria? --- ## Quality Audit - [ ] Quantitative β-hCG documented with date, time, and serial values - [ ] β-hCG trend calculated (% rise or decline in 48 hours) - [ ] Discriminatory zone defined (institutional threshold stated) - [ ] TVUS findings documented (IUP present/absent, adnexal mass, free fluid) - [ ] Hemodynamic status documented - [ ] Risk factors for ectopic documented - [ ] Methotrexate eligibility criteria systematically checked (all elements) - [ ] Methotrexate protocol specified (single-dose, two-dose, or multi-dose) with dosing - [ ] Post-methotrexate monitoring schedule documented - [ ] Surgical indication documented (if operative management chosen) - [ ] Procedure type documented (salpingostomy vs. salpingectomy) with rationale - [ ] Rh status documented and RhoGAM administered/planned - [ ] Pathology confirmation of ectopic tissue documented (surgical cases) - [ ] Patient counseled on ectopic precautions (pain, bleeding, return to ED) - [ ] β-hCG follow-up schedule documented until < 5 IU/L --- ## Guidelines 1. **Never diagnose ectopic based on a single β-hCG** — serial values and ultrasound findings are required for diagnosis (unless ultrasound shows definitive extrauterine pregnancy with cardiac activity). 2. **The discriminatory zone is a guideline, not an absolute** — multiple gestations and early IUPs may not be visible at the traditional threshold; use caution before intervening on a desired pregnancy. 3. **A rising β-hCG does not exclude ectopic** — ectopic pregnancies can show normal-appearing rises in up to 21% of cases. 4. **Methotrexate is not risk-free** — it requires reliable patient follow-up; do not administer if the patient cannot return for serial monitoring. 5. **Ruptured ectopic is a surgical emergency** — hemodynamic instability with a positive pregnancy test and free fluid mandates immediate operative intervention without waiting for β-hCG trends. 6. **Salpingectomy is preferred when the contralateral tube is healthy** — it eliminates the risk of persistent ectopic and recurrence in the same tube. 7. **Follow β-hCG to zero after ANY ectopic management** — persistent trophoblastic tissue occurs in 5–20% of salpingostomy cases and requires surveillance. 8. **Always give RhoGAM to Rh-negative patients** — ectopic pregnancy is a sensitizing event.